Heparin Tainting Deliberate

I found this report accidentally in a Parkinson's search, because the CEO of Baxter happens to be one Robert Parkinson. The Chicago Tribune reports that Parkinson called the contamination of its heparin supplies a "deliberate adulteration scheme" by suppliers in China. (PlagueBlog is shocked that such a thing could happen.)

The scale of the scandal over tainted heparin continued to expand. David Strunce, chief executive of Wisconsin-based Scientific Protein, acknowledged that the company has no way of knowing which of 12 different suppliers might have introduced foreign matter into the heparin supply chain. Strunce also claimed Chinese regulators have interfered with his company's efforts to investigate the matter.
The FDA has tallied more than 80 reports of deaths and more than 1,000 adverse events associated with patients in the U.S. who had one or more allergic reactions to heparin products, including those sold by Baxter, since Jan. 1, 2007.

As a result, the Chicago Tribune also reports, Baxter is considering getting out of the heparin business altogether:

The product generates $30 million of Baxter's more than $11 billion in annual sales, and Wall Street analysts asked Parkinson last week whether it was worth the legal risks and liability to remain in the business given that sales are so small.
"We haven't made a decision whether or not we are going to re-enter [the market] with heparin," Parkinson told analysts.

PlagueBlog recommends producing drugs, including their ingredients, domestically.